Exhale

The official blog of the Lung Institute.

Innovative Cellular Therapy Provider Raises Awareness for the “Lesser-Known” Third Leading Cause of Death in the U.S.

5 Nov 2013
| Under Press | Posted by | 0 Comments
COPD Awareness

Lung Institute Supports National COPD Awareness Month by Spreading the Word about Lung Disease Prevention and Treatment

Tampa, Fla. (November 5, 2013) – Chronic obstructive pulmonary disease (COPD) is a progressive form of lung disease that includes emphysema and chronic bronchitis. As the third leading cause of death in the United States and a top five cause of mortality across the globe, raising awareness for COPD is essential to prolonging and improving the lives of people with COPD and other chronic lung diseases.

24 million U.S. adults have evidence of impaired lung function, indicating a probable COPD diagnosis.

Once thought of as being a “man’s disease,” the prevalence of COPD among women has grown significantly. In 2011, women surpassed men for the tenth consecutive year of having a higher rate of chronic bronchitis diagnosis. The numbers speak for themselves with 3.3 million U.S. men diagnosed compared to 6.8 million women.

Anti-smoking campaigns have become common across the United States. Although cigarette smoking is the number one cause of COPD, it isn’t the only risk factor. Occupational dust and chemicals, air pollution, heredity and secondhand smoke are all causing this life altering disorder. With so many people diagnosed, or needing to be diagnosed with COPD, education about prevention and treatment options is essential.

As the nationwide leader for cellular therapys for COPD, the Lung Institute supports National COPD Awareness Month and the US COPD Coalition. Through the entire month of November, the Lung Institute is raising awareness through factual and insightful social media posts, as well as blog articles on subjects including the importance of pulmonary cellular therapys to reduce COPD symptoms and to improve people’s quality of life.

About Lung Institute

The Lung Institute is a leading medical provider of regenerative cellular therapy for lung diseases such as COPD, pulmonary fibrosis and interstitial lung disease. Founded in 2013 in Tampa, Fla., the Lung Institute currently has clinics in Tampa, Fla., Nashville, Tenn., Scottsdale, Ariz., Pittsburgh, Pa. and Dallas, Texas. For more information, please visit www.lunginstitute.com or call (800) 729-3065.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.